Assessment of Aspirin and Clopidogrel Resistance in Patients Undergoing Cardiovascular Surgery: A Single-Center Cross-Sectional Study

• Published in: Turkish journal of haematology Vol. 41; no. 2; pp. 105 - 112
• Main Authors: Özer, Abdullah, Demirtaş, Hüseyin, Tak, Sercan, Koçak, Başak, Yiğiter, Eda Nur, Oktar, Gürsel Levent, Kaya, Zühre
• Format: Journal Article
• Language: English
• Published: Turkey Galenos Publishing House 30.05.2024
• Subjects: Aged; antiplatelet therapy; Aspirin - pharmacology; Aspirin - therapeutic use; cardiovascular disorder; Cardiovascular Surgical Procedures - adverse effects; Clopidogrel - pharmacology; Clopidogrel - therapeutic use; Coronary Artery Disease - drug therapy; Coronary Artery Disease - surgery; Cross-Sectional Studies; Drug Resistance; Female; Humans; lumiaggregometry; Male; Middle Aged; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; platelet function analyzer-100; Platelet Function Tests; Antiplatelet therapy; Cardiovascular disorder; Lumiaggregometry; Platelet Function Analyzer-100
• ISSN: 1300-7777; 1308-5263
• DOI: 10.4274/tjh.galenos.2024.2024.0043

We aimed to investigate antiplatelet drug resistance utilizing light transmission-lumiaggregometry (LT-LA) and the Platelet Function Analyzer-100 (PFA-100) in patients undergoing cardiovascular surgery. The study included 60 patients diagnosed with stable coronary artery disease and peripheral vascular diseases that required surgery. Participants were divided into three groups: patients receiving aspirin (ASA) (n=21), patients receiving clopidogrel (CLO) (n=19), and patients receiving dual therapy (ASA+CLO) (n=20). Aggregation and secretion tests by LT-LA and closure time by the PFA-100 were used to measure antiplatelet drug resistance. Based on the adenosine diphosphate (ADP)-induced aggregation test, 43% of patients were resistant to ASA, 22% to CLO, and 15% to dual therapy. Diabetes, hypertension, and hyperlipidemia were the most commonly identified comorbid disorders. In patients with comorbid risk factors, the median value of platelet aggregation response to ADP was significantly higher in the ASA group than in the CLO and dual therapy groups (p=0.0001). In patients receiving ASA monotherapy, the maximum amplitude of aggregation response to platelet agonists was ≥70% in 43% of patients for ADP and 28% for collagen by LT-LA. Elevated ADP (≥0.29 nmol) and collagen (≥0.41 nmol)-induced adenosine triphosphate release were found by LT-LA in 66% of patients utilizing an ADP agonist and 80% of patients using a collagen agonist undergoing ASA therapy. Closure times obtained with the PFA-100 were normal in 28% of patients using collagen-ADP cartridges and 62% of patients using collagen-epinephrine (CEPI) cartridges who received ASA. Recurrent thrombosis and bleeding were observed in 12 (20%) patients with cardiovascular disease. Three of these individuals (25%) showed ASA resistance with normal responses to ADP-induced aggregation (≥70%) and secretion (≥0.29 nmol), as well as normal CEPI closure times. Our findings suggest that antiplatelet drug monitoring by LT-LA and PFA-100 may be useful for high-risk and complicated cardiovascular patients.